Novartis6d
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029. The company remains on track to deliver core operating ...
Novartis8d
Novartis ranks first in 2024 Access to Medicine Index
Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...
Novartis19h
Career Search
Explore opportunities with Novartis below.
Novartis6d
Addressing unmet needs for inherited neuromuscular diseases
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
Novartis12d
Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTOâ„¢
Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a ...
Novartis4d
Career search
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis8d
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants ...